mRNA CMV Vaccine Pipeline — PatSnap Eureka
mRNA Vaccine Pipeline for Congenital CMV Prevention
Human cytomegalovirus is the most common congenital viral infection globally — affecting 30,000–40,000 U.S. infants annually. With no licensed vaccine, mRNA-LNP platforms are leading a new wave of maternal immunization innovation. Explore the patent landscape with PatSnap Eureka.
Why Congenital CMV Is a Highest-Priority Vaccine Target
Human cytomegalovirus (hCMV) is a herpesvirus (Herpesviridae family) acquired primarily through contact with infectious mucosal secretions or in utero, with the capacity to establish latency after primary infection. CMV seroprevalence in the United States is approximately 50.4%, rising to 60–100% in resource-limited regions — making seronegative pregnant women a large and identifiable at-risk population.
Primary maternal infection during pregnancy transmits to the fetus in approximately 30–35% of cases. Approximately 12% of neonates born to mothers with primary CMV infection during pregnancy develop symptomatic congenital CMV (cCMV), which can result in sensorineural hearing loss, neurodevelopmental disorders, and other sequelae. The U.S. Institute of Medicine and the National Vaccine Program Office have designated CMV vaccine development as a highest-priority national health imperative — a designation explicitly cited across multiple ModernaTX patent filings.
No licensed CMV vaccine currently exists. This unmet need has catalyzed an intense wave of mRNA-based and alternative-platform vaccine innovation, analyzed here using patent and literature data from PatSnap's innovation intelligence platform. The dataset is predominantly patent-driven, consistent with the advanced commercial stage of this therapeutic area.
Key Antigens Driving CMV Vaccine Design
Five molecular targets appear consistently across mRNA, MVA, viral vector, and DNA vaccine platforms — each addressing a distinct aspect of CMV pathogenesis and vertical transmission.
Pentameric Glycoprotein Complex (gH/gL/UL128/UL130/UL131A)
The most frequently recurring target across the entire dataset. Results from ModernaTX, City of Hope, Merck, Virginia Commonwealth University, and Princeton University all converge on the pentameric complex as the critical determinant of epithelial and endothelial cell infection — the cell types mediating vertical (transplacental) CMV transmission. Princeton University's patent explicitly discloses that pUL128 and pUL130 are required for infection of non-fibroblast cell types.
6 assignees independently filing on this targetGlycoprotein B (gB)
Universally co-encoded in multi-antigen designs across mRNA, MVA, and DNA platforms. ModernaTX filings specify gB as the sixth mRNA component in their six-antigen formulation. gB is the primary mediator of fibroblast-tropic infection and a key target for heterogeneous neutralizing antibody responses. The early Vical codon-optimized plasmid vaccine specifically deleted the membrane anchor and endocellular domains of gB to optimize immunogenicity.
Present in 5 assignees' formulationsPhosphoprotein pp65 (UL83 Tegument Protein)
Present as a cellular immunity target in ModernaTX multi-antigen designs (co-encoded with pentamer complex and gB), MVA vectors (City of Hope), alphavirus replicons (AlphaVax), and the Hookipa Biotech arenavirus vector. The UL83/pp65 protein is consistently cited as the immunodominant T cell antigen in hCMV infection, directly relevant to cell-mediated maternal protection and fetal viral clearance mechanisms.
Immunodominant T cell antigenUL128 Epitopic Subregions (VCU Mapping)
Virginia Commonwealth University has specifically mapped high-titer neutralizing epitopes to amino acid residues 27–46 of UL130 and residues 90–106 of UL131, proposing chimeric/fusion peptide vaccines targeting these subregions — a more minimal antigen design strategy relative to full-length pentamer encoding. This approach enables precision targeting of the highest-value neutralizing epitopes within the pentameric complex.
Minimal antigen design strategyCMV Vaccine Patent Landscape: Key Metrics
Quantitative signals from patent data retrieved via PatSnap Eureka, illustrating modality distribution and antigen target frequency across the retrieved dataset.
Antigen Target Frequency Across CMV Vaccine Patent Dataset
Pentameric complex leads all targets, cited by 6 distinct assignees — reflecting convergent IP pressure on epithelial/endothelial cell neutralization.
CMV Vaccine Modality Distribution in Retrieved Patent Dataset
mRNA/LNP filings (ModernaTX) account for the dominant share of CMV vaccine IP activity, followed by viral vector and MVA approaches.
CMV Vaccine Platforms: From mRNA to Viral Vectors
Six distinct vaccine modalities are represented in this patent dataset, ranging from mRNA-LNP formulations to conditionally replication-defective live CMV platforms — each with distinct mechanistic rationale and safety profiles relevant to pregnant populations.
mRNA Vaccines Formulated in Lipid Nanoparticles (LNPs)
More than 25 distinct patent filings from ModernaTX across at least 10 jurisdictions. In vitro transcribed mRNA polynucleotides encoding one or more hCMV antigenic polypeptides are formulated in lipid nanoparticles for intracellular delivery. Upon cellular uptake, ribosomes translate the mRNA to endogenously produce viral antigens that are structurally intact, correctly folded, and human-glycosylated — mimicking wild-type viral infection without genome integration, nuclear entry, or replication. The platform is explicitly described as producing "balanced immune responses comprising both cellular and humoral immunity, without many of the risks associated with DNA or attenuated virus vaccination" — a safety-relevant claim for pregnant populations.
Preclinical NHP data disclosedModified Vaccinia Ankara (MVA) Viral Vector Vaccines
City of Hope uses modified vaccinia Ankara (MVA) as a viral vector into which multiple HCMV antigen-encoding DNA sequences are inserted, co-expressed from a single promoter via IRES and 2A peptide linking sequences. The UL128 pentameric complex is the central immunogen, with optional co-delivery of gB, pp65, and immediate-early proteins IE1/IE2 to engage both humoral and cellular immune arms. A 2025 WO filing describes a next-generation reconstituted synthetic MVA (rsMVA) platform designed for improved stability and immunogenicity, signaling continued iterative development.
rsMVA next-gen platform (2025)Who Holds the CMV Vaccine IP?
Patent filings are heavily concentrated among a small number of assignees, with commercial IP activity strongly dominating over academic literature signals in this dataset.
| Assignee | Primary Modality | Filing Jurisdictions | Key Antigens | Status |
|---|---|---|---|---|
| ModernaTX, Inc. | mRNA / LNP | US, WO, EP, CA, AU, BR, MX, IN, IL, KR, TW, JP, CN (13+) | gH, gL, UL128, UL130, UL131A, gB, pp65 | Dominant |
| Oregon Health & Science University | CMV Viral Vector | US, WO, JP, SG, MX, IL, CL, CO, TN, PL, CA, CN (12+) | Heterologous antigens; MHC-E T cell engineering | Active |
| City of Hope | MVA Viral Vector | JP, CN, WO | UL128 pentamer, gB, pp65, IE1/IE2 | Active |
| Merck Sharp & Dohme Corp. | CRD-CMV (Live Attenuated) | MX, PL, PT, RS | Pentameric gH complex (UL128, UL130, UL131, gH, gL) | Platform |
| Vir Biotechnology, Inc. | HCMV Vector (licensee/successor of OHSU) | WO, JP, BR | HCMV vector production and delivery | Active |
| Princeton University / VCU / UC | Subunit / Diagnostics | Various | Pentamer subunits; congenital biomarkers | Academic |
Need freedom-to-operate analysis across these assignees?
PatSnap Eureka maps claim overlaps, jurisdiction gaps, and licensing signals in real time.
Key Strategic Implications for CMV Vaccine Developers
Patent landscape signals from PatSnap Eureka reveal critical IP positioning, competitive risks, and open innovation opportunities in the congenital CMV prevention space.
ModernaTX Holds a Dominant mRNA Patent Position
ModernaTX holds a dominant patent position in mRNA-based hCMV vaccination, with filings spanning the broadest antigen combinations, LNP formulation variations, and global jurisdictions. Any competing mRNA vaccine developer targeting the congenital CMV indication will need to design around ModernaTX's pentamer-gB-pp65 multi-antigen co-formulation claims or pursue licenses. The pending 2025 US application suggests the portfolio is still actively expanding.
Pentameric Complex Is an IP Bottleneck Target
Multiple assignees have independently filed on the pentameric complex (gH/gL/UL128/UL130/UL131A) in different modalities — mRNA, MVA, CRD-CMV, subunit — creating a dense IP landscape around the dominant neutralization epitope for epithelial/vertical infection. Developers must conduct freedom-to-operate analysis across at least six assignees' pentamer-related claims.
Combination Approaches Converging Across Platforms
The most prominent emerging approach in this dataset is the simultaneous co-delivery of six separate mRNA polynucleotides encoding gH, gL, UL128, UL130, UL131A, and gB in a single LNP formulation — a combinatorial design intended to simultaneously induce pentamer-blocking antibodies (anti-epithelial cell infection) and gB-blocking antibodies (anti-fibroblast infection). ModernaTX's 2022 US/WO filings add pp65 as a seventh antigen to incorporate a cellular immune component, suggesting a "balanced humoral + cellular" combination strategy relevant to maternal protection.
OHSU's iterative filings (2018–2024 across multiple jurisdictions) increasingly specify combinatorial microRNA recognition element (MRE) insertions — both myeloid-specific miR-142-3p and endothelial-specific miR-126-3p targets — to precisely tune CD8+ T cell responses between MHC-Ia, MHC-II, and MHC-E restriction classes. This MHC-E optimization strategy may be adapted for HCMV-specific vaccination to engage non-classical immune surveillance pathways in CMV-seronegative pregnant women.
The co-occurrence in this dataset of molecular biomarker diagnostics (University of California, GeneFron Ltd.) alongside vaccine platforms suggests an emerging combination strategy: prophylactic immunization of seronegative women of reproductive age, with prenatal monitoring using virion RNA or host biomarker diagnostics to assess protection efficacy and detect breakthrough fetal infection. This integrated approach — analyzed further on PatSnap's life sciences intelligence platform — addresses the full unmet need and may present a differentiated regulatory and commercial proposition. For data integration capabilities, see PatSnap's open API.
Hookipa Biotech AG's 2021 ES patent describes a replication-deficient arenavirus vector expressing gB (with cytoplasmic/transmembrane domain deletions) or pp65 — representing an emerging non-CMV viral vector platform for CMV antigen delivery with safety advantages in immunocompromised or pregnant populations. For the broader regulatory context of maternal vaccines, see guidance from the FDA and the EMA.
mRNA CMV Vaccine Pipeline — key questions answered
Human cytomegalovirus (hCMV) is the most common congenital viral infection globally, affecting approximately 30,000–40,000 infants annually in the United States alone — representing 0.6–2% of live births. Primary maternal infection during pregnancy transmits to the fetus in approximately 30–35% of cases.
The pentameric complex — comprising gH, gL, UL128, UL130, and UL131A — is the dominant target for inducing neutralizing antibodies against epithelial and endothelial cell infection. Epithelial and endothelial cells play a key role in both horizontal and vertical (transplacental) CMV transmission, making high-titer neutralizing antibodies against the pentameric complex directly relevant to congenital infection prevention.
The neutralization benchmarks specified in key U.S. and PCT filings include: geometric mean titers of at least 3-fold against epithelial cell infection, geometric mean ratios of 9–41 against epithelial cell infection, or 4–8-fold against fibroblast infection. In preclinical data disclosed in the Australian patent filing, the hCMV pentamer mRNA vaccine induced neutralization titers in mice comparable to or exceeding CytoGam® (a hyperimmune globulin used clinically for prophylaxis).
ModernaTX's 2022 US/WO filings describe the simultaneous co-delivery of six separate mRNA polynucleotides encoding gH, gL, UL128, UL130, UL131A, and gB in a single LNP formulation. Later filings add pp65 as a seventh antigen to incorporate a cellular immune component, suggesting a balanced humoral and cellular combination strategy relevant to maternal protection.
Key assignees in this dataset include: Oregon Health & Science University (CMV vector technology with MHC-E restricted T cell responses), City of Hope (MVA-vector-based multi-antigen vaccines), Merck Sharp & Dohme Corp. (conditionally replication-defective live CMV platform), Hookipa Biotech AG (arenavirus vector expressing gB or pp65), Princeton University, Virginia Commonwealth University, University of California, Vical Incorporated, and AlphaVax Inc.
No licensed CMV vaccine currently exists. The U.S. Institute of Medicine and the National Vaccine Program Office have designated CMV vaccine development as a highest-priority national health imperative. All immunogenicity data retrieved in this analysis is preclinical — no retrieved results contain references to Phase 2 or Phase 3 clinical trial data, regulatory submissions, or approved product status.
Still have questions? Let PatSnap Eureka answer them for you.
Ask Eureka About CMV Vaccine PatentsAccelerate Your CMV Vaccine Research with AI-Powered Patent Intelligence
Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D — map the full congenital CMV patent landscape, identify FTO risks, and surface open IP opportunities in minutes.
References
- Human cytomegalovirus vaccine — ModernaTX, Inc., 2021, CA [Patent]
- Human cytomegalovirus vaccine — ModernaTX, Inc., 2022, US [Patent]
- Human cytomegalovirus vaccine — ModernaTX, Inc., 2022, WO [Patent]
- Human cytomegalovirus vaccine — ModernaTX, Inc., 2023, IN [Patent]
- Human cytomegalovirus RNA vaccines — ModernaTX, Inc., 2020, US [Patent]
- Human cytomegalovirus RNA vaccines — ModernaTX, Inc., 2019, US [Patent]
- Human cytomegalovirus vaccine — ModernaTX, Inc., 2021, WO [Patent]
- Human cytomegalovirus vaccine — ModernaTX, Inc., 2019, EP [Patent]
- Human cytomegalovirus vaccine — ModernaTX, Inc., 2019, AU [Patent]
- Human cytomegalovirus vaccine — ModernaTX, Inc., 2018, WO [Patent]
- Human cytomegalovirus vaccine — ModernaTX, Inc., 2022, AU [Patent]
- Human cytomegalovirus RNA vaccines — ModernaTX, Inc., 2025, US [Patent]
- MVA vaccines for delivery of UL128 complex and prevention of CMV infection — City of Hope, 2018, JP [Patent]
- MVA vectors for the expression of multiple cytomegalovirus (CMV) antigens and their uses — City of Hope, 2021, JP [Patent]
- Stable and immunogenic CMV vaccine — City of Hope, 2025, WO [Patent]
- Delivery of UL128 complex and MVA vaccine for prevention of CMV infection — City of Hope, 2020, JP [Patent]
- A conditional replicating cytomegalovirus as a vaccine for CMV — Merck Sharp & Dohme Corp., 2017, RS [Patent]
- A conditional replicating cytomegalovirus as a vaccine for CMV — Merck Sharp & Dohme Corp., 2014, MX [Patent]
- Cytomegalovirus vectors eliciting T cells restricted by major histocompatibility complex E molecules — Oregon Health & Science University, 2018, US [Patent]
- CMV vector containing microRNA recognition elements — Oregon Health & Science University, 2022, JP [Patent]
- CMV vector containing microRNA recognition elements — Oregon Health & Science University, 2019, JP [Patent]
- Alphavirus-based cytomegalovirus vaccines — AlphaVax Inc., 2009, PT [Patent]
- Codon-optimized polynucleotide-based vaccine against human cytomegalovirus infection — Vical Incorporated, 2006, JP [Patent]
- Centers for Disease Control and Prevention — CMV (Cytomegalovirus) and Congenital CMV Infection
- National Academies of Sciences, Engineering, and Medicine — Vaccine Priority Reports
- U.S. Food and Drug Administration — Vaccine Development Guidance
- European Medicines Agency — Vaccine Regulatory Guidelines
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches. It represents a snapshot of innovation signals within this dataset only and should not be interpreted as a comprehensive view of the full field, clinical pipeline, or regulatory landscape.
PatSnap Eureka searches patents and research to answer instantly.